June 9, 2020 / 12:46 PM / a month ago

BRIEF-OPKO Health Reports Positive Results Of Study Of Somatrogon

June 9 (Reuters) - OPKO Health Inc:

* OPKO HEALTH ANNOUNCES POSITIVE TOP-LINE RESULTS OF PHASE 3 EFFICACY AND SAFETY STUDY OF SOMATROGON FOR THE TREATMENT OF JAPANESE CHILDREN WITH GROWTH HORMONE DEFICIENCY

* OPKO HEALTH INC - JAPAN PHASE 3 CLINICAL TRIAL MET ITS PRIMARY AND SECONDARY OBJECTIVES

* OPKO HEALTH INC - ONE PATIENT IN GENOTROPIN GROUP DISCONTINUED TREATMENT IN STUDY DUE TO ADVERSE EVENTS

* OPKO HEALTH INC - FINDINGS WERE CONSISTENT WITH RESULTS PREVIOUSLY REPORTED IN PHASE 3 GLOBAL STUDY

* OPKO HEALTH INC - WEEKLY SOMATROGON ADMINISTRATION WAS GENERALLY WELL-TOLERATED

* OPKO HEALTH - JAPAN PHASE 3 TRIAL OF SOMATROGON DEMONSTRATED THAT EFFICACY & SAFETY OF SOMATROGON ADMINISTERED WEEKLY WAS COMPARABLE TO GENOTROPIN Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below